BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
Provided By GlobeNewswire
Last update: May 27, 2025
NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the Company’s request to continue its listing on The Nasdaq Stock Market.
Read more at globenewswire.com
